http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2025, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Tue, 19 Aug 2025 10:15:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/InnoCare+Releases+2025+Interim+Results+and+Business+Highlights/25222745.html <p> BEIJING--(BUSINESS WIRE)-- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on cancer and autoimmune diseases, today announced the 2025 interim results as of 30 June 2025. </p><p> <b>Significant Revenue Growth from Orelabrutinib</b> </p><p> Total Revenue of InnoCare increased by 74.3% year-on-year (YoY) to RMB731.4 million1 for the six months ended 30 June 2025, primarily attributable to the robust sales growth of orelabrutinib and license-out revenue from Prolium. Drug sales increased by 53.5% YoY to RMB641.2 million in the first half of 2025, driven by coverage expansion, an increase in the number of patients treated by orelabrutinib, especially in http://www.streetinsider.com/Press+Releases/InnoCare+Releases+2025+Interim+Results+and+Business+Highlights/25222745.html Tue, 19 Aug 2025 10:15:00 -0400 09969 688428 A.35846118 A.60012013 O.00018297 O.38236026 O.45125312 http://www.streetinsider.com/Press+Releases/InnoCare+Releases+2025+Interim+Results+and+Business+Highlights/25222745.html <p> BEIJING--(BUSINESS WIRE)-- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on cancer and autoimmune diseases, today announced the 2025 interim results as of 30 June 2025. </p><p> <b>Significant Revenue Growth from Orelabrutinib</b> </p><p> Total Revenue of InnoCare increased by 74.3% year-on-year (YoY) to RMB731.4 million1 for the six months ended 30 June 2025, primarily attributable to the robust sales growth of orelabrutinib and license-out revenue from Prolium. Drug sales increased by 53.5% YoY to RMB641.2 million in the first half of 2025, driven by coverage expansion, an increase in the number of patients treated by orelabrutinib, especially in http://www.streetinsider.com/Press+Releases/InnoCare+Releases+2025+Interim+Results+and+Business+Highlights/25222745.html Tue, 19 Aug 2025 10:15:00 -0400 09969 688428 A.35846118 A.60012013 O.00018297 O.38236026 O.45125312 http://www.streetinsider.com/Press+Releases/InnoCare+Releases+2025+Interim+Results+and+Business+Highlights/25222745.html <p> BEIJING--(BUSINESS WIRE)-- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on cancer and autoimmune diseases, today announced the 2025 interim results as of 30 June 2025. </p><p> <b>Significant Revenue Growth from Orelabrutinib</b> </p><p> Total Revenue of InnoCare increased by 74.3% year-on-year (YoY) to RMB731.4 million1 for the six months ended 30 June 2025, primarily attributable to the robust sales growth of orelabrutinib and license-out revenue from Prolium. Drug sales increased by 53.5% YoY to RMB641.2 million in the first half of 2025, driven by coverage expansion, an increase in the number of patients treated by orelabrutinib, especially in http://www.streetinsider.com/Press+Releases/InnoCare+Releases+2025+Interim+Results+and+Business+Highlights/25222745.html Tue, 19 Aug 2025 10:15:00 -0400 09969 688428 A.35846118 A.60012013 O.00018297 O.38236026 O.45125312 http://www.streetinsider.com/Press+Releases/InnoCare+Releases+2025+Interim+Results+and+Business+Highlights/25222745.html <p> BEIJING--(BUSINESS WIRE)-- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on cancer and autoimmune diseases, today announced the 2025 interim results as of 30 June 2025. </p><p> <b>Significant Revenue Growth from Orelabrutinib</b> </p><p> Total Revenue of InnoCare increased by 74.3% year-on-year (YoY) to RMB731.4 million1 for the six months ended 30 June 2025, primarily attributable to the robust sales growth of orelabrutinib and license-out revenue from Prolium. Drug sales increased by 53.5% YoY to RMB641.2 million in the first half of 2025, driven by coverage expansion, an increase in the number of patients treated by orelabrutinib, especially in http://www.streetinsider.com/Press+Releases/InnoCare+Releases+2025+Interim+Results+and+Business+Highlights/25222745.html Tue, 19 Aug 2025 10:15:00 -0400 09969 688428 A.35846118 A.60012013 O.00018297 O.38236026 O.45125312 http://www.streetinsider.com/Press+Releases/InnoCare+Releases+2025+Interim+Results+and+Business+Highlights/25222745.html <p> BEIJING--(BUSINESS WIRE)-- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on cancer and autoimmune diseases, today announced the 2025 interim results as of 30 June 2025. </p><p> <b>Significant Revenue Growth from Orelabrutinib</b> </p><p> Total Revenue of InnoCare increased by 74.3% year-on-year (YoY) to RMB731.4 million1 for the six months ended 30 June 2025, primarily attributable to the robust sales growth of orelabrutinib and license-out revenue from Prolium. Drug sales increased by 53.5% YoY to RMB641.2 million in the first half of 2025, driven by coverage expansion, an increase in the number of patients treated by orelabrutinib, especially in http://www.streetinsider.com/Press+Releases/InnoCare+Releases+2025+Interim+Results+and+Business+Highlights/25222745.html Tue, 19 Aug 2025 10:15:00 -0400 09969 688428 A.35846118 A.60012013 O.00018297 O.38236026 O.45125312 http://www.streetinsider.com/Press+Releases/InnoCare+Releases+2025+Interim+Results+and+Business+Highlights/25222745.html <p> BEIJING--(BUSINESS WIRE)-- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on cancer and autoimmune diseases, today announced the 2025 interim results as of 30 June 2025. </p><p> <b>Significant Revenue Growth from Orelabrutinib</b> </p><p> Total Revenue of InnoCare increased by 74.3% year-on-year (YoY) to RMB731.4 million1 for the six months ended 30 June 2025, primarily attributable to the robust sales growth of orelabrutinib and license-out revenue from Prolium. Drug sales increased by 53.5% YoY to RMB641.2 million in the first half of 2025, driven by coverage expansion, an increase in the number of patients treated by orelabrutinib, especially in http://www.streetinsider.com/Press+Releases/InnoCare+Releases+2025+Interim+Results+and+Business+Highlights/25222745.html Tue, 19 Aug 2025 10:15:00 -0400 09969 688428 A.35846118 A.60012013 O.00018297 O.38236026 O.45125312 http://www.streetinsider.com/Press+Releases/InnoCare+Releases+2025+Interim+Results+and+Business+Highlights/25222745.html <p> BEIJING--(BUSINESS WIRE)-- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on cancer and autoimmune diseases, today announced the 2025 interim results as of 30 June 2025. </p><p> <b>Significant Revenue Growth from Orelabrutinib</b> </p><p> Total Revenue of InnoCare increased by 74.3% year-on-year (YoY) to RMB731.4 million1 for the six months ended 30 June 2025, primarily attributable to the robust sales growth of orelabrutinib and license-out revenue from Prolium. Drug sales increased by 53.5% YoY to RMB641.2 million in the first half of 2025, driven by coverage expansion, an increase in the number of patients treated by orelabrutinib, especially in http://www.streetinsider.com/Press+Releases/InnoCare+Releases+2025+Interim+Results+and+Business+Highlights/25222745.html Tue, 19 Aug 2025 10:15:00 -0400 09969 688428 A.35846118 A.60012013 O.00018297 O.38236026 O.45125312 http://www.streetinsider.com/Business+Wire/InnoCare+Releases+2025+Interim+Results+and+Business+Highlights/25222745.html <p> BEIJING--(BUSINESS WIRE)-- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on cancer and autoimmune diseases, today announced the 2025 interim results as of 30 June 2025. </p><p> <b>Significant Revenue Growth from Orelabrutinib</b> </p><p> Total Revenue of InnoCare increased by 74.3% year-on-year (YoY) to RMB731.4 million1 for the six months ended 30 June 2025, primarily attributable to the robust sales growth of orelabrutinib and license-out revenue from Prolium. Drug sales increased by 53.5% YoY to RMB641.2 million in the first half of 2025, driven by coverage expansion, an increase in the number of patients treated by orelabrutinib, especially in http://www.streetinsider.com/Business+Wire/InnoCare+Releases+2025+Interim+Results+and+Business+Highlights/25222745.html Tue, 19 Aug 2025 10:15:00 -0400 09969 688428 A.35846118 A.60012013 O.00018297 O.38236026 O.45125312 http://www.streetinsider.com/Business+Wire/InnoCare+Releases+2025+Interim+Results+and+Business+Highlights/25222745.html <p> BEIJING--(BUSINESS WIRE)-- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on cancer and autoimmune diseases, today announced the 2025 interim results as of 30 June 2025. </p><p> <b>Significant Revenue Growth from Orelabrutinib</b> </p><p> Total Revenue of InnoCare increased by 74.3% year-on-year (YoY) to RMB731.4 million1 for the six months ended 30 June 2025, primarily attributable to the robust sales growth of orelabrutinib and license-out revenue from Prolium. Drug sales increased by 53.5% YoY to RMB641.2 million in the first half of 2025, driven by coverage expansion, an increase in the number of patients treated by orelabrutinib, especially in http://www.streetinsider.com/Business+Wire/InnoCare+Releases+2025+Interim+Results+and+Business+Highlights/25222745.html Tue, 19 Aug 2025 10:15:00 -0400 09969 688428 A.35846118 A.60012013 O.00018297 O.38236026 O.45125312 http://www.streetinsider.com/Business+Wire/InnoCare+Releases+2025+Interim+Results+and+Business+Highlights/25222745.html <p> BEIJING--(BUSINESS WIRE)-- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on cancer and autoimmune diseases, today announced the 2025 interim results as of 30 June 2025. </p><p> <b>Significant Revenue Growth from Orelabrutinib</b> </p><p> Total Revenue of InnoCare increased by 74.3% year-on-year (YoY) to RMB731.4 million1 for the six months ended 30 June 2025, primarily attributable to the robust sales growth of orelabrutinib and license-out revenue from Prolium. Drug sales increased by 53.5% YoY to RMB641.2 million in the first half of 2025, driven by coverage expansion, an increase in the number of patients treated by orelabrutinib, especially in http://www.streetinsider.com/Business+Wire/InnoCare+Releases+2025+Interim+Results+and+Business+Highlights/25222745.html Tue, 19 Aug 2025 10:15:00 -0400 09969 688428 A.35846118 A.60012013 O.00018297 O.38236026 O.45125312 http://www.streetinsider.com/Business+Wire/InnoCare+Releases+2025+Interim+Results+and+Business+Highlights/25222745.html <p> BEIJING--(BUSINESS WIRE)-- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on cancer and autoimmune diseases, today announced the 2025 interim results as of 30 June 2025. </p><p> <b>Significant Revenue Growth from Orelabrutinib</b> </p><p> Total Revenue of InnoCare increased by 74.3% year-on-year (YoY) to RMB731.4 million1 for the six months ended 30 June 2025, primarily attributable to the robust sales growth of orelabrutinib and license-out revenue from Prolium. Drug sales increased by 53.5% YoY to RMB641.2 million in the first half of 2025, driven by coverage expansion, an increase in the number of patients treated by orelabrutinib, especially in http://www.streetinsider.com/Business+Wire/InnoCare+Releases+2025+Interim+Results+and+Business+Highlights/25222745.html Tue, 19 Aug 2025 10:15:00 -0400 09969 688428 A.35846118 A.60012013 O.00018297 O.38236026 O.45125312 http://www.streetinsider.com/Business+Wire/InnoCare+Releases+2025+Interim+Results+and+Business+Highlights/25222745.html <p> BEIJING--(BUSINESS WIRE)-- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on cancer and autoimmune diseases, today announced the 2025 interim results as of 30 June 2025. </p><p> <b>Significant Revenue Growth from Orelabrutinib</b> </p><p> Total Revenue of InnoCare increased by 74.3% year-on-year (YoY) to RMB731.4 million1 for the six months ended 30 June 2025, primarily attributable to the robust sales growth of orelabrutinib and license-out revenue from Prolium. Drug sales increased by 53.5% YoY to RMB641.2 million in the first half of 2025, driven by coverage expansion, an increase in the number of patients treated by orelabrutinib, especially in http://www.streetinsider.com/Business+Wire/InnoCare+Releases+2025+Interim+Results+and+Business+Highlights/25222745.html Tue, 19 Aug 2025 10:15:00 -0400 09969 688428 A.35846118 A.60012013 O.00018297 O.38236026 O.45125312 http://www.streetinsider.com/Business+Wire/InnoCare+Releases+2025+Interim+Results+and+Business+Highlights/25222745.html <p> BEIJING--(BUSINESS WIRE)-- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on cancer and autoimmune diseases, today announced the 2025 interim results as of 30 June 2025. </p><p> <b>Significant Revenue Growth from Orelabrutinib</b> </p><p> Total Revenue of InnoCare increased by 74.3% year-on-year (YoY) to RMB731.4 million1 for the six months ended 30 June 2025, primarily attributable to the robust sales growth of orelabrutinib and license-out revenue from Prolium. Drug sales increased by 53.5% YoY to RMB641.2 million in the first half of 2025, driven by coverage expansion, an increase in the number of patients treated by orelabrutinib, especially in http://www.streetinsider.com/Business+Wire/InnoCare+Releases+2025+Interim+Results+and+Business+Highlights/25222745.html Tue, 19 Aug 2025 10:15:00 -0400 09969 688428 A.35846118 A.60012013 O.00018297 O.38236026 O.45125312 http://www.streetinsider.com/Business+Wire/InnoCare+Releases+2025+Interim+Results+and+Business+Highlights/25222745.html <p> BEIJING--(BUSINESS WIRE)-- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on cancer and autoimmune diseases, today announced the 2025 interim results as of 30 June 2025. </p><p> <b>Significant Revenue Growth from Orelabrutinib</b> </p><p> Total Revenue of InnoCare increased by 74.3% year-on-year (YoY) to RMB731.4 million1 for the six months ended 30 June 2025, primarily attributable to the robust sales growth of orelabrutinib and license-out revenue from Prolium. Drug sales increased by 53.5% YoY to RMB641.2 million in the first half of 2025, driven by coverage expansion, an increase in the number of patients treated by orelabrutinib, especially in http://www.streetinsider.com/Business+Wire/InnoCare+Releases+2025+Interim+Results+and+Business+Highlights/25222745.html Tue, 19 Aug 2025 10:15:00 -0400 09969 688428 A.35846118 A.60012013 O.00018297 O.38236026 O.45125312 http://www.streetinsider.com/Press+Releases/InnoCare+Announces+Approval+of+Clinical+Trial+of+a+Novel+ADC+ICP-B794+in+China/25018606.html <p> BEIJING--(BUSINESS WIRE)-- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today the approval of the Investigational New Drug (IND) by the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) to conduct the clinical trial of a novel B7-H3 targeted ADC ICP-B794. </p><p> ICP-B794 is a novel ADC comprising a humanized anti-B7-H3 monoclonal antibody conjugated to potent in-house developed payload via a protease-cleavable linker. This combination ensures precise targeting of tumor cells while minimizing off-target effects, offering a promising treatment for solid tumors http://www.streetinsider.com/Press+Releases/InnoCare+Announces+Approval+of+Clinical+Trial+of+a+Novel+ADC+ICP-B794+in+China/25018606.html Thu, 03 Jul 2025 23:03:00 -0400 09969 688428 O.45125312 http://www.streetinsider.com/Press+Releases/InnoCare+Announces+Approval+of+Clinical+Trial+of+a+Novel+ADC+ICP-B794+in+China/25018606.html <p> BEIJING--(BUSINESS WIRE)-- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today the approval of the Investigational New Drug (IND) by the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) to conduct the clinical trial of a novel B7-H3 targeted ADC ICP-B794. </p><p> ICP-B794 is a novel ADC comprising a humanized anti-B7-H3 monoclonal antibody conjugated to potent in-house developed payload via a protease-cleavable linker. This combination ensures precise targeting of tumor cells while minimizing off-target effects, offering a promising treatment for solid tumors http://www.streetinsider.com/Press+Releases/InnoCare+Announces+Approval+of+Clinical+Trial+of+a+Novel+ADC+ICP-B794+in+China/25018606.html Thu, 03 Jul 2025 23:03:00 -0400 09969 688428 O.45125312 http://www.streetinsider.com/Press+Releases/InnoCare+Announces+Approval+of+Clinical+Trial+of+a+Novel+ADC+ICP-B794+in+China/25018606.html <p> BEIJING--(BUSINESS WIRE)-- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today the approval of the Investigational New Drug (IND) by the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) to conduct the clinical trial of a novel B7-H3 targeted ADC ICP-B794. </p><p> ICP-B794 is a novel ADC comprising a humanized anti-B7-H3 monoclonal antibody conjugated to potent in-house developed payload via a protease-cleavable linker. This combination ensures precise targeting of tumor cells while minimizing off-target effects, offering a promising treatment for solid tumors http://www.streetinsider.com/Press+Releases/InnoCare+Announces+Approval+of+Clinical+Trial+of+a+Novel+ADC+ICP-B794+in+China/25018606.html Thu, 03 Jul 2025 23:03:00 -0400 09969 688428 O.45125312 http://www.streetinsider.com/Business+Wire/InnoCare+Announces+Approval+of+Clinical+Trial+of+a+Novel+ADC+ICP-B794+in+China/25018606.html <p> BEIJING--(BUSINESS WIRE)-- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today the approval of the Investigational New Drug (IND) by the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) to conduct the clinical trial of a novel B7-H3 targeted ADC ICP-B794. </p><p> ICP-B794 is a novel ADC comprising a humanized anti-B7-H3 monoclonal antibody conjugated to potent in-house developed payload via a protease-cleavable linker. This combination ensures precise targeting of tumor cells while minimizing off-target effects, offering a promising treatment for solid tumors http://www.streetinsider.com/Business+Wire/InnoCare+Announces+Approval+of+Clinical+Trial+of+a+Novel+ADC+ICP-B794+in+China/25018606.html Thu, 03 Jul 2025 23:03:00 -0400 09969 688428 O.45125312 http://www.streetinsider.com/Business+Wire/InnoCare+Announces+Approval+of+Clinical+Trial+of+a+Novel+ADC+ICP-B794+in+China/25018606.html <p> BEIJING--(BUSINESS WIRE)-- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today the approval of the Investigational New Drug (IND) by the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) to conduct the clinical trial of a novel B7-H3 targeted ADC ICP-B794. </p><p> ICP-B794 is a novel ADC comprising a humanized anti-B7-H3 monoclonal antibody conjugated to potent in-house developed payload via a protease-cleavable linker. This combination ensures precise targeting of tumor cells while minimizing off-target effects, offering a promising treatment for solid tumors http://www.streetinsider.com/Business+Wire/InnoCare+Announces+Approval+of+Clinical+Trial+of+a+Novel+ADC+ICP-B794+in+China/25018606.html Thu, 03 Jul 2025 23:03:00 -0400 09969 688428 O.45125312 http://www.streetinsider.com/Business+Wire/InnoCare+Announces+Approval+of+Clinical+Trial+of+a+Novel+ADC+ICP-B794+in+China/25018606.html <p> BEIJING--(BUSINESS WIRE)-- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today the approval of the Investigational New Drug (IND) by the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) to conduct the clinical trial of a novel B7-H3 targeted ADC ICP-B794. </p><p> ICP-B794 is a novel ADC comprising a humanized anti-B7-H3 monoclonal antibody conjugated to potent in-house developed payload via a protease-cleavable linker. This combination ensures precise targeting of tumor cells while minimizing off-target effects, offering a promising treatment for solid tumors http://www.streetinsider.com/Business+Wire/InnoCare+Announces+Approval+of+Clinical+Trial+of+a+Novel+ADC+ICP-B794+in+China/25018606.html Thu, 03 Jul 2025 23:03:00 -0400 09969 688428 O.45125312 http://www.streetinsider.com/Press+Releases/Data+of+InnoCare%E2%80%99s+Robust+Hemato-Oncology+Pipelines+Presented+at+the+European+Hematology+Association+%28EHA%29+2025+Congress/24932734.html <p> BEIJING--(BUSINESS WIRE)-- Latest data of InnoCare’s (HKEX: 09969; SSE: 688428) robust oncology pipelines were presented at the ongoing European Hematology Association (EHA) 2025 Congress. </p><p> <b>Poster Presentation:</b> </p><p class="bwmarginl1"> <b>1. First Presentation of Efficacy and Safety Data for First-Line Treatment of CLL/SLL with BCL2 Inhibitor Mesutoclax in Combination with BTK Inhibitor Orelabrutinib (Abstract No.: PS1567)</b> </p><p> The study showed that mesutoclax (100 and 125 mg) in combination with orelabrutinib was safe and well tolerated in patients with treatment naïve (TN) CLL/SLL. Substantial efficacy was observed, with early high undetectable MRD (uMRD) rate. </p><p> 42 patients with TN CLL/SLL were enrolled (mesutoclax 100 mg, n=21; 125 http://www.streetinsider.com/Press+Releases/Data+of+InnoCare%E2%80%99s+Robust+Hemato-Oncology+Pipelines+Presented+at+the+European+Hematology+Association+%28EHA%29+2025+Congress/24932734.html Thu, 12 Jun 2025 22:49:00 -0400 09969 688428 O.45125312 http://www.streetinsider.com/Press+Releases/Data+of+InnoCare%E2%80%99s+Robust+Hemato-Oncology+Pipelines+Presented+at+the+European+Hematology+Association+%28EHA%29+2025+Congress/24932734.html <p> BEIJING--(BUSINESS WIRE)-- Latest data of InnoCare’s (HKEX: 09969; SSE: 688428) robust oncology pipelines were presented at the ongoing European Hematology Association (EHA) 2025 Congress. </p><p> <b>Poster Presentation:</b> </p><p class="bwmarginl1"> <b>1. First Presentation of Efficacy and Safety Data for First-Line Treatment of CLL/SLL with BCL2 Inhibitor Mesutoclax in Combination with BTK Inhibitor Orelabrutinib (Abstract No.: PS1567)</b> </p><p> The study showed that mesutoclax (100 and 125 mg) in combination with orelabrutinib was safe and well tolerated in patients with treatment naïve (TN) CLL/SLL. Substantial efficacy was observed, with early high undetectable MRD (uMRD) rate. </p><p> 42 patients with TN CLL/SLL were enrolled (mesutoclax 100 mg, n=21; 125 http://www.streetinsider.com/Press+Releases/Data+of+InnoCare%E2%80%99s+Robust+Hemato-Oncology+Pipelines+Presented+at+the+European+Hematology+Association+%28EHA%29+2025+Congress/24932734.html Thu, 12 Jun 2025 22:49:00 -0400 09969 688428 O.45125312 http://www.streetinsider.com/Press+Releases/Data+of+InnoCare%E2%80%99s+Robust+Hemato-Oncology+Pipelines+Presented+at+the+European+Hematology+Association+%28EHA%29+2025+Congress/24932734.html <p> BEIJING--(BUSINESS WIRE)-- Latest data of InnoCare’s (HKEX: 09969; SSE: 688428) robust oncology pipelines were presented at the ongoing European Hematology Association (EHA) 2025 Congress. </p><p> <b>Poster Presentation:</b> </p><p class="bwmarginl1"> <b>1. First Presentation of Efficacy and Safety Data for First-Line Treatment of CLL/SLL with BCL2 Inhibitor Mesutoclax in Combination with BTK Inhibitor Orelabrutinib (Abstract No.: PS1567)</b> </p><p> The study showed that mesutoclax (100 and 125 mg) in combination with orelabrutinib was safe and well tolerated in patients with treatment naïve (TN) CLL/SLL. Substantial efficacy was observed, with early high undetectable MRD (uMRD) rate. </p><p> 42 patients with TN CLL/SLL were enrolled (mesutoclax 100 mg, n=21; 125 http://www.streetinsider.com/Press+Releases/Data+of+InnoCare%E2%80%99s+Robust+Hemato-Oncology+Pipelines+Presented+at+the+European+Hematology+Association+%28EHA%29+2025+Congress/24932734.html Thu, 12 Jun 2025 22:49:00 -0400 09969 688428 O.45125312 http://www.streetinsider.com/Business+Wire/Data+of+InnoCare%E2%80%99s+Robust+Hemato-Oncology+Pipelines+Presented+at+the+European+Hematology+Association+%28EHA%29+2025+Congress/24932734.html <p> BEIJING--(BUSINESS WIRE)-- Latest data of InnoCare’s (HKEX: 09969; SSE: 688428) robust oncology pipelines were presented at the ongoing European Hematology Association (EHA) 2025 Congress. </p><p> <b>Poster Presentation:</b> </p><p class="bwmarginl1"> <b>1. First Presentation of Efficacy and Safety Data for First-Line Treatment of CLL/SLL with BCL2 Inhibitor Mesutoclax in Combination with BTK Inhibitor Orelabrutinib (Abstract No.: PS1567)</b> </p><p> The study showed that mesutoclax (100 and 125 mg) in combination with orelabrutinib was safe and well tolerated in patients with treatment naïve (TN) CLL/SLL. Substantial efficacy was observed, with early high undetectable MRD (uMRD) rate. </p><p> 42 patients with TN CLL/SLL were enrolled (mesutoclax 100 mg, n=21; 125 http://www.streetinsider.com/Business+Wire/Data+of+InnoCare%E2%80%99s+Robust+Hemato-Oncology+Pipelines+Presented+at+the+European+Hematology+Association+%28EHA%29+2025+Congress/24932734.html Thu, 12 Jun 2025 22:49:00 -0400 09969 688428 O.45125312 http://www.streetinsider.com/Business+Wire/Data+of+InnoCare%E2%80%99s+Robust+Hemato-Oncology+Pipelines+Presented+at+the+European+Hematology+Association+%28EHA%29+2025+Congress/24932734.html <p> BEIJING--(BUSINESS WIRE)-- Latest data of InnoCare’s (HKEX: 09969; SSE: 688428) robust oncology pipelines were presented at the ongoing European Hematology Association (EHA) 2025 Congress. </p><p> <b>Poster Presentation:</b> </p><p class="bwmarginl1"> <b>1. First Presentation of Efficacy and Safety Data for First-Line Treatment of CLL/SLL with BCL2 Inhibitor Mesutoclax in Combination with BTK Inhibitor Orelabrutinib (Abstract No.: PS1567)</b> </p><p> The study showed that mesutoclax (100 and 125 mg) in combination with orelabrutinib was safe and well tolerated in patients with treatment naïve (TN) CLL/SLL. Substantial efficacy was observed, with early high undetectable MRD (uMRD) rate. </p><p> 42 patients with TN CLL/SLL were enrolled (mesutoclax 100 mg, n=21; 125 http://www.streetinsider.com/Business+Wire/Data+of+InnoCare%E2%80%99s+Robust+Hemato-Oncology+Pipelines+Presented+at+the+European+Hematology+Association+%28EHA%29+2025+Congress/24932734.html Thu, 12 Jun 2025 22:49:00 -0400 09969 688428 O.45125312